Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for production of t cell population

A cell group and cell technology, applied in the field of preparing T cell groups useful in the medical field, can solve problems such as inability to obtain sufficient effects

Inactive Publication Date: 2013-09-25
TAKARA HOLDINGS
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, in the dendritic cell infusion therapy or peptide vaccine therapy that is expected to induce antigen-specific CTL in vivo, for example, in patients with advanced cancer, there are few naive T cells that can be induced by CTL, so in many cases, sufficient CTL cannot be obtained. Effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for production of t cell population
  • Method for production of t cell population
  • Method for production of t cell population

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0138] Example 1CD45RA + CD62L + Analysis of T cells

[0139] (1) Isolation and preservation of PBMC

[0140] Blood components were collected from healthy human donors who gave informed consent, and then the collected blood was diluted 2-fold with phosphate-buffered saline (hereinafter referred to as PBS), spread on Ficoll-paque (manufactured by Amasham Biosystems), and fed at 600 × g Centrifuge for 20 minutes. Peripheral blood mononuclear cells (hereinafter referred to as PBMCs) in the middle layer were collected by a pipette and washed. The collected PBMCs were suspended in a preservation solution containing 90% FBS (manufactured by Cambrex) / 10% DMSO, or CP-1 (manufactured by Jidong Pharmaceutical Co., Ltd.) containing 8% human serum albumin (manufactured by Baxter, hereinafter referred to as HSA). ) and RPMI1640 medium (manufactured by Sigma) in an equal volume mixture, and stored in liquid nitrogen. When expanding T cell culture, these preserved PBMCs were rapidly tha...

Embodiment 2

[0155] Example 2CD45RA + CCR7 + Analysis of T cells

[0156] (1) Expanded culture of T cell population

[0157] The PBMC prepared in Example 1-(1) was suspended in AIM-V (hereinafter referred to as 3% AIM-V) containing 3% human AB serum, and the concentration was 1×10 6 cells / mL, prepare the cell solution, and then add 3% AIM-V to the plate prepared in Example 1-(2) immobilized with anti-human CD3 antibody, or immobilized with anti-human CD3 antibody and CH To the -296 plate, add the above-mentioned cell solution at 1 mL / well, respectively. Add IL-2 to a final concentration of 1000 U / mL and place the plates in 5% CO 2 , and cultured at 37°C (cultivation day 0). On the 4th day from the beginning of culture, each group was diluted with AIM-V containing 1% human AB serum (volume 6mL), the concentration was 0.075×10 6 cells / mL, transfer the culture medium to a 12.5cm cell without any fixation 2 In the cell culture flask, add IL-2 with a final concentration of 500U / mL. The ...

Embodiment 3

[0175] Example 3 Using CH-296 to expand CD45RA in the cultured T cell population + CCR7 + T cells and CD45RA - CCR7 - Analysis of cytokine production of T cells

[0176] (1) Expanded culture of T cell population

[0177] Suspend the PBMC prepared in Example 1-(1) in GT-T503 medium (manufactured by TAKARA BIO, hereinafter referred to as 0.5% GT-T503) containing 0.5% human AB serum and 0.2% HSA, at a concentration of 0.25 ×10 6 cells / mL, prepare the cell solution, then add 0.5% GT-T503 to the plate immobilized with anti-human CD3 antibody prepared in Example 1-(2), or immobilized with anti-human CD3 antibody and To the CH-296 plate, the above-mentioned cell solution was added at 1 mL / well. Add IL-2 to a final concentration of 1000 U / mL and place the plates in 5% CO2 , and cultured at 37°C (cultivation day 0). On the 4th day after the start of culture, the culture solution of each group was diluted about 8 times with 0.5% GT-T503, and 6 mL of the diluted solution was trans...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for preparing a T cell population, wherein the T cell population expresses CD45RA and expresses at least one selected from the group consisting of CD62L, CCR7, CD27, and CD28, characterized in that the method comprises the step of culturing a cell population comprising a T cell, in the presence of fibronectin, a fragment thereof or a mixture thereof.

Description

technical field [0001] The present invention relates to methods for preparing populations of T cells useful in the medical field. Background technique [0002] A living organism protects the body from foreign bodies primarily through an immune response. The immune system is composed of various cells and the soluble factors they produce. Among them, white blood cells, especially lymphocytes, play a key role. Lymphocytes are divided into two main types, B lymphocytes (hereinafter, referred to as B cells) and T lymphocytes (hereinafter, referred to as T cells), both of which specifically recognize antigens and act thereon to protect an organism. [0003] Among T cells in the periphery, CD4 T cells with CD (cluster of differentiation) 4 and CD8 T cells with CD8 markers accounted for the majority. The majority of CD4 T cells are called helper T cells (hereinafter referred to as T H ), which are related to auxiliary antibody production or induction of various immune responses,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/06A61K35/14A61P1/16A61P31/04A61P31/10A61P31/12A61P31/16A61P35/00A61P37/04C12N5/10A61K35/76C07K14/78C12N15/09A61K35/17C12N5/07C12N5/0783C12N15/86
CPCA61K35/17A61K39/00C12N2740/10043C12N2501/515A61K39/0011C12N5/0636C12N2501/58A61K2039/5158C12N15/86A61K38/19A61P1/16A61P31/04A61P31/10A61P31/12A61P31/16A61P35/00A61P37/04C12N2533/52A61K39/46434A61K39/4611A61K39/464491A61K39/464499A61K39/461A61K39/4621A61K2239/38A61K2300/00C12N5/06A61K35/14A61K35/76C12N5/10
Inventor 榎龙嗣加藤彰子村木信子出野美津子円居隆宏佐川裕章加藤郁之进
Owner TAKARA HOLDINGS